Artwork
iconShare
 
Manage episode 514210221 series 3576337
Content provided by The Lancet. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.

  continue reading

693 episodes